| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner | Director
3 companies
Andrew J. Schwab is Director at CAMP, with reported holdings spanning 3 companies. Andrew J. Schwab's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $50.8M at current prices.
Our model assigns Andrew J. Schwab a middling insider score of 61/100, based on 5 past trades. Over a 12-month horizon, 80.0% of those trades were profitable, with an average 12-month return of +35.5%.
Andrew J. Schwab's largest disclosed position is in ELVN as Director, worth about $43.1M.
Andrew J. Schwab has 25 Form 4 filings on record from February 2023 to September 2026, across 3 companies: Director, 10% Owner at Skye Bioscience (SKYE), 2023–2026; Director at Camp4 Therapeutics (CAMP), 2024–2026; Director, 10% Owner at Enliven Therapeutics (ELVN), 2023.
The 56 reported transactions were 30 open-market sales, 12 option or other derivative awards, 10 stock awards and 3 conversions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $10.0M and 8 sales worth about $5.5M.
The only open-market purchase was 909,090 shares of CAMP at an average $11.00 on October 15, 2024, about $10.0M. Twelve months later CAMP was down 68%.
The largest open-market sale was 266,337 shares of SKYE at an average $6.57 on September 13, 2024, about $1.8M. Twelve months later SKYE was down 29%.
None of the 8 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 23, 2026 | SKYE Skye Bioscience, Inc. | Director, 10% Owner | Sell | 148,079 | $1.62 | $239,555.19 | -100% | - | - | |
| Sep 16, 2026 | SKYE Skye Bioscience, Inc. | Director, 10% Owner | Sell | 33,892 | $1.91 | $64,733.72 | -85.8% | - | - | |
| Aug 27, 2026 | CAMP Camp4 Therapeutics Corporation | Director | Sell | 400,000 | $4.04 | $1,616,000.00 | -16.4% | - | - | |
| Aug 24, 2026 | CAMP Camp4 Therapeutics Corporation | Director | Sell | 10 | $4.50 | $45.00 | - | - | - | |
| Aug 21, 2026 | CAMP Camp4 Therapeutics Corporation | Director | Sell | 191,865 | $4.59 | $879,718.72 | -7.3% | - | - | |
| Aug 20, 2026 | SKYE Skye Bioscience, Inc. | Director, 10% Owner | Sell | 375,840 | $0.37 | $140,313.00 | -3.9% | - | - | |
| Aug 22, 2025 | SKYE Skye Bioscience, Inc. | Director, 10% Owner | Sell | 231,405 | $3.46 | $800,548.50 | -80.1% | -62.0% | -91.5% | |
| Oct 15, 2024 | CAMP Camp4 Therapeutics Corp | Director, 10% Owner | Buy | 909,090 | $11.00 | $9,999,990.00 | +53.0% | -63.3% | -68.0% | |
| Sep 13, 2024 | SKYE Skye Bioscience, Inc. | - | Sell | 266,337 | $6.57 | $1,750,352.22 | -80.1% | -44.2% | -29.2% |